AbbVie ABBV
AbbVie is a global pharmaceutical company that develops and commercializes medicines in areas such as immunology (Humira, Skyrizi), oncology, and aesthetics (Botox). AbbVie has solid financial health (6.61) and excellent business quality (8.21), with an operating margin of 40.03% and a gross margin of 72.79%. Earnings growth of 290.40% is exceptional, although the P/E of 74.46 is high; however, the forward P/E of 16.25 and PEG of 0.54 suggest the market is already pricing in a normalization.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
AbbVie is a global pharmaceutical company that develops and commercializes medicines in areas such as immunology (Humira, Skyrizi), oncology, and aesthetics (Botox). AbbVie has solid financial health (6.61) and excellent business quality (8.21), with an operating margin of 40.03% and a gross margin of 72.79%. Earnings growth of 290.40% is exceptional, although the P/E of 74.46 is high; however, the forward P/E of 16.25 and PEG of 0.54 suggest the market is already pricing in a normalization.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.6 |
| Quality / Moat | 8.2 |
| Valuation | 4.6 |
| Growth | 8.4 |
| Dividend | 2.9 |
| Momentum | 5.6 |
| Risk & Context | 8.5 |
OVERALL SCORE: 6.7/10
Context and risks
AbbVie is a US-based pharmaceutical company with a significant portion of its revenue coming from Humira, which has already lost patent exclusivity. Regulatory pressure on drug pricing in the US is a structural risk for the sector, although AbbVie has a solid balance sheet and a well-supported dividend.
News considered in the analysis
- AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth — La IA podría acelerar el descubrimiento de fármacos, pero es una oportunidad especulativa a largo plazo sin impacto tangible en los beneficios a corto plazo.
- Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. — La perspectiva de tipos más altos durante más tiempo presiona el múltiplo de valoración de las farmacéuticas de gran capitalización, aunque AbbVie tiene un balance sólido y un dividendo bien respaldado.
- How to Build $7,250 a Month in Dividend Income Without Owning a Single Yield Trap — Listado genérico de ideas de ingresos sin información específica sobre AbbVie.
- What Does AbbVie (ABBV) Need To Prove With Its Latest Pipeline Moves? — Análisis especulativo sobre la cartera de productos sin hechos concretos o nuevas noticias.
- Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines — La actividad de acuerdos en el sector biotecnológico es positiva para la valoración de los activos de AbbVie y podría indicar un mayor interés en sus plataformas.
Verdict: Hold; the valuation is demanding but expected growth and business quality justify the premium.
Main risk: The main risk is regulatory pressure on drug pricing in the US, which could impact revenue from Humira and other key products.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →